| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/17/2009 | US20090232735 Use of fructose-based therapies for the treatment of cancer |
| 09/17/2009 | US20090232731 Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis |
| 09/17/2009 | US20090232730 Method of producing immunoliposomes and compositions thereof |
| 09/17/2009 | US20090229600 Method Of Forming An Aerosol For Inhalation Delivery |
| 09/17/2009 | DE202008012494U1 Pharmazeutische Zusammensetzung für die nasale Applikation A pharmaceutical composition for nasal administration |
| 09/17/2009 | DE102008014077A1 New borrelidin derivatives are janus kinase 3 inhibitors useful e.g. for treating tumor, microbial infection, immune disorder and ophthalmic disease, inhibiting angiogenesis, and manufacturing herbicides and insecticides against arthropods |
| 09/17/2009 | DE102008013622A1 Pharmazeutische Zusammensetzung zur Diagnose oder Behandlung des Plasmozytoms A pharmaceutical composition for the diagnosis or treatment of multiple myeloma |
| 09/17/2009 | DE102008013587A1 Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung Heteroaryl substituted dicyanopyridines and their use |
| 09/17/2009 | DE102007063495A1 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel 19-nor-steroid derivatives with a 15α, 16α-methyl group and a saturated 17,17-spirolactone, the use of these derivatives and pharmaceutical compositions containing them |
| 09/17/2009 | CA2755014A1 Methods and compositions for controlled delivery of phytochemical agents |
| 09/17/2009 | CA2750859A1 The compounds as the estrogen related receptors modulators and the uses thereof |
| 09/17/2009 | CA2734208A1 Mitochondrially delivered anti-cancer compounds |
| 09/17/2009 | CA2732764A1 Methods and compositions for treating inflammation and inflammation-related pathologies |
| 09/17/2009 | CA2729613A1 Methotrexate adjuvants to reduce toxicity and methods for using the same |
| 09/17/2009 | CA2727792A1 Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
| 09/17/2009 | CA2719097A1 Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness |
| 09/17/2009 | CA2719074A1 Novel method for the production of sulphonylpyrroles as hdac inhibitors |
| 09/17/2009 | CA2719071A1 (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide salts |
| 09/17/2009 | CA2718494A1 Steroidal ligands and their use in gene switch modulation |
| 09/17/2009 | CA2718463A1 Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts |
| 09/17/2009 | CA2718407A1 Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
| 09/17/2009 | CA2718400A1 Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| 09/17/2009 | CA2718393A1 Pyridylaminoacetic acid compound |
| 09/17/2009 | CA2718384A1 Formulations with sanguinarine, chelerythrine or chelidonine for the treatment of warts, verrucas and psoriatic plaques |
| 09/17/2009 | CA2718382A1 C2orf18 as target gene for cancer therapy and diagnosis |
| 09/17/2009 | CA2718364A1 A topical ectoparasiticide composition |
| 09/17/2009 | CA2718345A1 Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate |
| 09/17/2009 | CA2718276A1 Enzymatic substrates for multiple detection systems |
| 09/17/2009 | CA2718271A1 Azetidine and cyclobutane derivatives as jak inhibitors |
| 09/17/2009 | CA2718262A1 Formulations of vitamin k analogs for topical use |
| 09/17/2009 | CA2718252A1 Bicyclic pyrrole compound |
| 09/17/2009 | CA2718241A1 Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors |
| 09/17/2009 | CA2718238A1 Stabilized 1,25-dihydroxyvitamin d2 and method of making same |
| 09/17/2009 | CA2718233A1 Compositions and methods of use of compounds to increase cancer patient survival time |
| 09/17/2009 | CA2718222A1 Synbiotic mixture |
| 09/17/2009 | CA2718194A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors |
| 09/17/2009 | CA2718189A1 Nanoparticulate compositions of angiogenesis inhibitors |
| 09/17/2009 | CA2718175A1 Use of 4'-thio-2'-deoxynucleosides as anti orthopoxvirus agents |
| 09/17/2009 | CA2718166A1 Processes for preparing enantiomerically pure diol and dioxolane compounds |
| 09/17/2009 | CA2718138A1 Azaindole compounds for treatment of central nervous system disorders |
| 09/17/2009 | CA2718056A1 Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling |
| 09/17/2009 | CA2718038A1 Azabicyclo [3.2.1] octyl derivatives as 11 beta-hsdl modulators |
| 09/17/2009 | CA2718028A1 Formulation and method for the prevention and treatment of bone metastases or other bone diseases |
| 09/17/2009 | CA2718007A1 The use of medium chain dicarboxylic acids and derivates thereof in the treatment of metabolic disorders |
| 09/17/2009 | CA2718005A1 Mmp-2 and/or mmp-9 inhibitor |
| 09/17/2009 | CA2717991A1 Treatment for ocular-related disorders |
| 09/17/2009 | CA2717947A1 Orally-disintegrating solid preparation |
| 09/17/2009 | CA2717904A1 Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| 09/17/2009 | CA2717867A1 Activated nitric oxide donors and methods of making and using thereof |
| 09/17/2009 | CA2717660A1 Therapy for disorders of the proximal digestive tract |
| 09/17/2009 | CA2717632A1 Therapeutic compounds |
| 09/17/2009 | CA2717529A1 Sulfonamides as zap-70 inhibitors |
| 09/17/2009 | CA2717497A1 Method for inhibiting the build-up of arterial plaque by administering fullerenes |
| 09/17/2009 | CA2717496A1 Compositions comprising notch1 sirna and methods of use thereof |
| 09/17/2009 | CA2717495A1 Fullerene therapies for inflammation |
| 09/17/2009 | CA2717488A1 Thiazolyl-dihydro-indazoles |
| 09/17/2009 | CA2717362A1 Vitamin d compounds and methods for reducing ocular hypertension (oht) |
| 09/17/2009 | CA2717351A1 A combination drug for treating vascular disorder |
| 09/17/2009 | CA2717326A1 Preparation of lenalidomide |
| 09/17/2009 | CA2717181A1 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| 09/17/2009 | CA2717169A1 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| 09/17/2009 | CA2717042A1 Methods, compositions, and kits for treating pain and pruritis |
| 09/17/2009 | CA2716918A1 Tricyclic derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| 09/17/2009 | CA2716907A1 2-aminoquinolines as 5-ht5a receptor antagonists |
| 09/17/2009 | CA2716857A1 Novel compounds as cannabinoid receptor ligands |
| 09/17/2009 | CA2716764A1 Novel use of zinc n-acetyltaurinate |
| 09/17/2009 | CA2716730A1 Substituted heterocycle fused gamma-carbolines solid |
| 09/17/2009 | CA2716724A1 Novel dosage and formulation |
| 09/17/2009 | CA2716723A1 Novel dosage and formulation |
| 09/17/2009 | CA2716679A1 Amido-thiophene compounds and their use |
| 09/17/2009 | CA2716101A1 Phytol as a cholesterol lowering agent |
| 09/17/2009 | CA2716079A1 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
| 09/17/2009 | CA2716058A1 Dna vaccines and methods for the prevention of transplantation rejection |
| 09/17/2009 | CA2715982A1 Methods of treating hyperacidic disorders |
| 09/17/2009 | CA2715585A1 Large particle size crystallised maltitol powder, method for preparing same and applications thereof, particularly in chocolate production |
| 09/17/2009 | CA2715110A1 Compounds for use in the treatment of neuropathic pain |
| 09/17/2009 | CA2715036A1 Therapies for cancer using isotopically substituted lysine |
| 09/17/2009 | CA2713367A1 Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof |
| 09/17/2009 | CA2712914A1 Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof |
| 09/17/2009 | CA2712629A1 Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 09/17/2009 | CA2712609A1 Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 09/17/2009 | CA2712489A1 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them |
| 09/17/2009 | CA2710801A1 2-benzoyl-imidazo(1,2-.alpha) pyridine derivatives, their preparation and their therapeutic application |
| 09/17/2009 | CA2710797A1 Imidazo[1,2-.alpha.]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics |
| 09/16/2009 | EP2100963A1 Method of vitamin production |
| 09/16/2009 | EP2100902A1 Methods for treating pain by administering an antagonist antibody against the nerve growth factor and an opioid analgesic, and compositions containing the same |
| 09/16/2009 | EP2100895A1 Tricyclic compound and medical use thereof |
| 09/16/2009 | EP2100894A1 Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| 09/16/2009 | EP2100893A1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 09/16/2009 | EP2100891A1 Inhibitors of tyrosine kinases |
| 09/16/2009 | EP2100890A1 Novel polynitrogenated systems as anti-hiv agents |
| 09/16/2009 | EP2100888A2 Process for the preparation of duloxetine hydrochloride |
| 09/16/2009 | EP2100882A1 (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts |
| 09/16/2009 | EP2100881A1 Pyrimidyl- or pyridinylaminobenzoic acid derivatives |
| 09/16/2009 | EP2100879A1 Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| 09/16/2009 | EP2100878A1 Novel method for the production of sulphonylpyrroles as HDAC inhibitors |
| 09/16/2009 | EP2100877A1 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 09/16/2009 | EP2100876A2 New compounds for the inhibition of rotamases and use thereof |
| 09/16/2009 | EP2100620A1 Nucleic acids encoding polyepitope polypeptides |
| 09/16/2009 | EP2100616A2 Composition of antigen and glycolipid adjuvant sublingual administration |